Crescent Grove Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Crescent Grove Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,500	Closed	-$276K	–	296
2021 Q2	$276K	Hold	1,500	–	–	0.03%	208
2021 Q1	$229K	Hold	1,500	–	–	0.03%	189
2020 Q4	$234K	Buy	+1,500	New	+$193K	0.03%	164

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Crescent Grove Advisors's ALXN Position: Q3 2021 in Review

Crescent Grove Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,500 shares — an estimated $276K sold.

Crescent Grove Advisors first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $276K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Crescent Grove Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Crescent Grove Advisors sold 1,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $276K.
Crescent Grove Advisors first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
Crescent Grove Advisors's Alexion Pharmaceuticals position peaked at $276K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Crescent Grove Advisors's 13F filing for Q3 2021, filed 26 Oct 2021.